The use of (18)F-Fluoro-deoxy-glucose positron emission tomography ((18)F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor

BACKGROUND: The phosphatidyl inositol 3 kinase (PI3K), AKT and mammalian target of rapamycin (mTOR) signal transduction pathway is frequently de-regulated and activated in human cancer and is an important therapeutic target. AZD8835 is a PI3K inhibitor, with selectivity against PI3K α and δ isoforms...

Descripción completa

Detalles Bibliográficos
Autores principales: Maynard, Juliana, Emmas, Sally-Ann, Ble, Francois-Xavier, Barjat, Herve, Lawrie, Emily, Hancox, Urs, Polanska, Urszula M., Pritchard, Alison, Hudson, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555689/
https://www.ncbi.nlm.nih.gov/pubmed/28806782
http://dx.doi.org/10.1371/journal.pone.0183048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555689/
https://www.ncbi.nlm.nih.gov/pubmed/28806782
http://dx.doi.org/10.1371/journal.pone.0183048

Ejemplares similares